ArticleMethods in molecular biology (Clifton, N.J.)2025
Quantification of Neutralizing Antibodies of Tick-Borne Viruses Using Focus Neutralization Assays.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tick-borne flaviviruses, such as Powassan virus (POWV) or Deer tick virus (DTV), can elicit robust humoral responses in animal models of disease (Hermanceet al., PLoS Negl Trop Dis 14(6):e0008359, 2020; Stone et al., Cell Rep 38(7):110388, 2022; Reynolds et al., Comp Med 67:232-241, 2017). Several aspects of humoral immunity to tick-borne flaviviruses are unknown; however, convalescent serum can offer partial protection against a POWV challenge naïve immune-competent animals (Stone et al., Cell Rep 38(7):110388, 2022). Accurately quantifying the neutralizing titers of protective antibodies allows us to determine the effectiveness of virus neutralization of a given sample. Understanding the efficacy of convalescent sera or antibody titers post-infection or vaccination facilitates identifying a potential correlate of protection.
Indexed as
Identifiers
40512315What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.